Verteporfin (CL 318952)

Catalog No.S1786 Synonyms: Visudyne

For research use only.

Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.

Verteporfin (CL 318952) Chemical Structure

CAS No. 129497-78-5

Selleck's Verteporfin (CL 318952) has been cited by 101 publications

Purity & Quality Control

Choose Selective VDA Inhibitors

Other VDA Products

Biological Activity

Description Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Targets
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
()
In vitro

Verteporfin is about four times more efficient in absorbing light at wavelengths that penetrate tissues best (i.e., around 700 nm) and thus provides a much higher cytotoxic effect than hematoporphyrin (10 times more in human adherent cell lines). Verteporfin is lipophilic and is more readily taken up by malignant or activated cells, compared with normal or resting cells. Verteporfin binds with LDL to form a complex, which is then taken up into proliferating cells (e.g., neovascular endothelial cells) probably via LDL receptors and endocytosis. Verteporfin therapy achieves complete angiographic occlusion of the neovascular compartment by thrombosis of vascular channels, following selective endothelial damage. Verteporfin therapy selectively induces reproducible and isolated choriocapillary occlusion without alteration of overlying photoreceptors or ganglion cells, as shown by light and electron microscopy. [1] Verteporfin conbined with light rapidly exhibits apoptotic changes reflected by caspase-3 and caspase-9 activation and PARP cleavage in HL-60 cells, changes that are blocked by the general caspase inhibitor ZVAD.fmk. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 NVnsc2o1TnWwY4Tpc44h[XO|YYm= MVv+NVAxKG6pL33M NGHo[lZFVVOR M3rQR4lv[3KnYYPld{BFVkFiZoLh[41mdnSjdHnvckBt\X[nbIO= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODZyN{exNEc,OTB4MEe3NVA9N2F-
HL-60 M{\6V4N6fG:2b4jpZ4l1gSCjc4PhfS=> NH3mN5l,OTByIH7nM41N MYjEUXNQ NYTEPJM2cW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MkXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB4MEe3NVAoRjFyNkC3O|ExRC:jPh?=
Jurkat NUH2PHhwSXCxcITvd4l{KGG|c3H5 NGTrfXB,OjhyIH7N M1rRWWROW09? NXPSVWI2cW6mdXPld{BiKEKlbD2yMYRmeGWwZHXueEBieG:ydH;zbZM> NGTqflA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUK0OVQyPSd-MUGyOFU1OTV:L3G+
RIF-1 M1zibWZ2dmO2aX;uJIF{e2G7 M1\PT|Eh|rypL33s Mmn5SG1UVw>? M1X4eIRm[3KnYYPld{BwgHmpZX6gZ49ve3WvcITpc44> NIKxZYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[xOVcyQCd-MUK2NVU4OTh:L3G+
RIF-1 MoL4Z5l1d3SxeHnjbZR6KGG|c3H5 NF;LfGMyKM7:Zz;tcC=> M1vhe2ROW09? MmfR[IVkemWjc3WgeI8hOjBiwsGgOUUh[2WubDDzeZJ3cX[jbB?= MnX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4MUW3NVgoRjF{NkG1O|E5RC:jPh?=
SVEC4-10 MVvGeY5kfGmxbjDhd5NigQ>? NV7uco0yOjByIH7nM41t NG\td2lFVVOR MWrpcoR2[2W|IH3pZ5JwfHWkdXzlJIRmeG:ueX3ldol7[XSrb36= NFGxeW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS2O|ExPid-MU[0OlcyODZ:L3G+
SVEC4-10 MVHGeY5kfGmxbjDhd5NigQ>? M2ryRlIxOCCwZz;tcC=> NWLRfldNTE2VTx?= MoTWbY5lfWOnczDzeJJme3NiYXP0bY4h\mmkZYKg[o9zdWG2aX;u MmPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2NkexNFYoRjF4NE[3NVA3RC:jPh?=
ARPE-19 M2G2U4N6fG:2b4jpZ4l1gSCjc4PhfS=> MYH+NE4yKM7:Zz;tcC=> MWDEUXNQ MVfzbI94eyCjIHTvd4Uu\GWyZX7k[Y51KHSxeHnjbZR6 NHHNXHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkm4O|kxPSd-MU[5PFc6ODV:L3G+
ARPE-19 MnniSpVv[3Srb36gZZN{[Xl? NG\E[IQxNjBzIN88[{9udA>? MUDEUXNQ M4nyUYlv[3KnYYPld{BXTUeIIHHu[EBz\WS3Y3XzJHBGTEZiZYjwdoV{e2mxbh?= M4fNZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OUi3PVA2Lz5zNkm4O|kxPTxxYU6=
Y-79 M3HGe2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXX3T3hbhjFizsznM41t MoDZSG1UVw>? Ml\3[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe2OEc,OTh3N{m3OlQ9N2F-
WERI-Rb1 MXfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1OxVZ4yKM7:Zz;tcC=> M{DzWWROW09? NEDM[4Fl\WO{ZXHz[ZMhemW2aX7vZoxie3SxbXGgZ4VtdCCycn;sbYZmemG2aX;u MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe2OEc,OTh3N{m3OlQ9N2F-
RB247C3 NETaTJNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1z5OZ4yKM7:Zz;tcC=> M4S1RmROW09? Mki4[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= NYjtXWs1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O|k4PjRpPkG4OVc6PzZ2PD;hQi=>
RB355 MkXFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYLB[|EzhjFizsznM41t NWrzVIg6TE2VTx?= NVLuNnNZ\GWlcnXhd4V{KHKndHnuc4Jt[XO2b33hJINmdGxicILvcIln\XKjdHnvci=> MljjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3OlQoRjF6NUe5O|Y1RC:jPh?=
RB383 NF3oNWFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= Mn3KglEh|rypL33s NF\6NodFVVOR NHzVR3dl\WO{ZXHz[ZMhemW2aX7vZoxie3SxbXGgZ4VtdCCycn;sbYZmemG2aX;u NEDrbmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3PVc3PCd-MUi1O|k4PjR:L3G+
hFibro MVPjfZRwfG:6aXPpeJkh[XO|YYm= NGXKe2MxNjViwsXnM41t NYrM[4d1TE2VTx?= M4P2S4Rm[3KnYYPld{B3cWGkaXzpeJkh[nliOE[sOUU> Ml;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEGxNVQoRjJ|NESxNVE1RC:jPh?=
pTMC NEfsT2NkgXSxdH;4bYNqfHliYYPzZZk> M13vRlAvPSEEtXevcYw> MUHEUXNQ M4\GZYRm[3KnYYPld{B3cWGkaXzpeJkh[nliOUKuPUU> NF;Mb4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0NVEyPCd-MkO0OFEyOTR:L3G+
hTMC MnHjZ5l1d3SxeHnjbZR6KGG|c3H5 MkS4NE42KML3Zz;tcC=> M2[3SWROW09? MVfk[YNz\WG|ZYOgeoli[mmuaYT5JIJ6KDh6Lkml MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2MUGxOEc,OjN2NEGxNVQ9N2F-
ARPE-19 MkjWZ5l1d3SxeHnjbZR6KGG|c3H5 MlrPNE42KML3Zz;tcC=> MnnqSG1UVw>? NWfrdWM4\GWlcnXhd4V{KH[rYXLpcIl1gSCkeTC1OU42LQ>? M1myW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESxNVE1Lz5{M{S0NVEyPDxxYU6=
Panc-1 MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGXySpEyOCEQvF2= NILyTWVFVVOR NX;YU2JZcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v MljRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkmwOlkoRjJ2ME[5NFY6RC:jPh?=
MIA PaCa-2 MXXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1XMO|ExKM7:TR?= MV3EUXNQ NUe5T|RvcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v NGr4fFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
BxPC-3 M4XWZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M1\BO|ExKM7:TR?= MXHEUXNQ NVjZbpVYcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHl? NFHNfYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
SU86.86 NEDxXGdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M2LvNVExKM7:TR?= MWfEUXNQ MlXhbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJINwdXCuZYTlcJk> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4OUC2PUc,OjRyNkmwOlk9N2F-
MCF-7 NYXXWpU{SXW2b4DoZYd6KGG|c3H5 NX25dVN7OTBizszN NGjGW4NFVVOR M1nkfolvcGmkaYTzJIdmdWOrdHHibY5mNWmwZIXj[YQh[XW2b4DoZYd6 NVfsbm4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlkxPjlpPkK0NFY6ODZ7PD;hQi=>
WERI MX\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NX\hc3hxhjFyIN88[{9udA>? NEPrNlFFVVOR MmPZbY5pcWKrdIOg[5Jwf3SqIH;mJJJmfGmwb3LsZZN1d22jIHPlcIx{ MmrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{exOFIoRjJ2OEO3NVQzRC:jPh?=
WERI M2\GemZ2dmO2aX;uJIF{e2G7 MnnsglExKM7:Zz;tcC=> MUTEUXNQ NUPwT2lH[myxY3vzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25? MojuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{exOFIoRjJ2OEO3NVQzRC:jPh?=
Y-79 NFzHVXZHfW6ldHnvckBie3OjeR?= MVv+NVAh|rypL33s MoDKSG1UVw>? NGHj[GZjdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdg>? Mnv0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{exOFIoRjJ2OEO3NVQzRC:jPh?=
Y-79 Ml\RSpVv[3Srb36gZZN{[Xl? NVi2XoRkhjFyIN88[{9udA>? NGL3[5FFVVOR MX3h[oZm[3S|IGnBVE1VTUGGIIDyc5RwNW:wY3;n[Y5mKHCjdHj3ZZk> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|N{G0Nkc,OjR6M{exOFI9N2F-
Y-79 MX;GeY5kfGmxbjDhd5NigQ>? NEHvUop,OTBizsznM41t NGrHXlZFVVOR MmPF[I94di2{ZXf1cIF1\XNicHz1dolxd3SnbnP5JI1iemuncjDPR3QuPA>? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|N{G0Nkc,OjR6M{exOFI9N2F-
Phototoxicity assay MUnCNVZHOTB? MX:yOEBpenN? M1rrdmlEPTBiPTCxMlA4KM7:TR?= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|NkO4PUc,OjdzM{[zPFk9N2F-
Phototoxicity assay NIDDdW5DOT[IMUC= NILJ[4YzPCCqcoO= NYLtdY1WUUN3MDC9JFEvOiEQvF2= M2rMfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Phototoxicity assay NXvRNJl6STN5NR?= MWGyOEBpenN? NX\ZUY9LUUN3MDC9JFIvODZizszN MkjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
Dark toxicity assay MkfSRlE3TjFy M2TLcVQ5KGi{cx?= MYPJR|UxKD1iMkSuPVIh|ryP M1yyblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay NYXYVndKSjF4RkGw M2LuTlQ5KGi{cx?= NGHJU49KSzVyIE2gNlUvODNizszN Mn7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
Dark toxicity assay M1TVc2E{PzV? MYW0PEBpenN? M2TJdmlEPTBiPTCzOk4{OyEQvF2= MnrlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
qHTS assay MkTWWGM{Og>? MmnNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN? NGXJbHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NWTjU2wyXS1{IF;T NHzkSWRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVT2yJG9UKGOnbHzz NULsWJVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay M{fMdGE3PzN? MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? Mkm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MYTERW9[ MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NVfVOm5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay Mnf5V4Fwey1{ NFHkd3FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NYjp[4pKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NFfTPGNDXC1|Nx?= MkHvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NYfWSlNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NHnwWVdTTA>? NVXaUWpOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| M1jERVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay M{H0cHNMNU5vU1i= MlvVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NV7TTnRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MkPXRnQuOTJ? M3TlfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NFHYXVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NFPpU|lOTyB4MzCoOk1VTyCUKR?= M3Oxb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= M3nWW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay Mn3UU2hUNTVy MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay NUDzR|A6Wmh2MR?= NUXQVlJpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NHmyVWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay MWHTTk1ISk1{ M13WfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NXjsTGFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay MWXTT{1PNU2F NF;RWmJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> M2DwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay MU\MRW4uPQ>? MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? NEj5Z2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Antitumor assay NFjmcm5DOT[IMUC= NVfLVlFGOiCvZz;r[y=> M2TTblIhcHK| MVfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDCNVZHOTBiY3XscJMhcW2ybHHueIVlKGmwIFO1O2JNNzZibX;1d4Uh[XO|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMjDt[{9s\yxiaY[gZYRucW6rc4TldoVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDpdpJi\GmjdHnvckB4cXSqIHzhd4VzKGG2IEG1NEBLN2OvJ{Kg[o9zKDFyIH3pcpM> MoGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
Assay
Methods Test Index PMID
Western blot ECAD / Vimentin / Sox2 / CD44 / CD133 ; c-Myc / Bcl-2 ; p-S6(S240/244) / p-4EBP1(S65) ; beta-catenin 30467925 29416644 28202507
Growth inhibition assay Cell viability 28042502
Immunofluorescence p-YAP(Y357) ; Calreticulin ; YAP1 28404908 30254296
In vivo Verteporfin can be used for angiographic visualization of choroidal vessels and CNV, which demonstrates that the photosensitizer accumulates rapidly in experimental CNV in monkeys. Verteporfin accumulates rapidly in the established vasculature of the choroid, RPE, and photoreceptors of rabbit eyes. Verteporfin reaches maximal tissue levels within 3 hours of intravenous injection, followed by a rapid decline within 24 hours in mice. Verteporfin is metabolized to a less active form in vivo and is cleared very rapidly, predominantly in the feces and a very small proportion excreted in urine. Verteporfin therapy effectively and selectively prevents fluorescein dye leakage from experimentally induced CNV in monkeys. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 100 mg/mL
(139.12 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 718.79
Formula

C41H42N4O8

CAS No. 129497-78-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC(=O)CCC1=C(C)C2=CC3=NC(=CC4=C(C)C(=C([NH]4)C=C5N=C(C=C1[NH]2)C(=C5C)CCC(O)=O)C=C)C6=CC=C(C(C(=O)OC)C36C)C(=O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04590664 Recruiting Drug: Verteporfin Glioblastoma|Recurrent Glioblastoma Emory University|National Cancer Institute (NCI) January 15 2021 Phase 1|Phase 2
NCT03797547 Active not recruiting Other: AFLIBERCEPT Myopic Choroidal Neovascularisation Poitiers University Hospital June 22 2018 --
NCT01846273 Completed Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham PDT Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy Novartis Pharmaceuticals|Novartis August 7 2013 Phase 4
NCT00423189 Terminated Drug: Ranibizumab (Lucentis)|Drug: 0.5mg ranibizumab Age-Related Macular Degeneration David M. Brown M.D.|Novartis Pharmaceuticals|Greater Houston Retina Research January 2007 Phase 4
NCT00403442 Terminated Device: Verteporfin Therapy/ Drug: Bevacizumab Macular Degeneration Vitreous -Retina- Macula Consultants of New York|QLT Inc. September 2006 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Verteporfin (CL 318952) | Verteporfin (CL 318952) ic50 | Verteporfin (CL 318952) price | Verteporfin (CL 318952) cost | Verteporfin (CL 318952) solubility dmso | Verteporfin (CL 318952) purchase | Verteporfin (CL 318952) manufacturer | Verteporfin (CL 318952) research buy | Verteporfin (CL 318952) order | Verteporfin (CL 318952) mouse | Verteporfin (CL 318952) chemical structure | Verteporfin (CL 318952) mw | Verteporfin (CL 318952) molecular weight | Verteporfin (CL 318952) datasheet | Verteporfin (CL 318952) supplier | Verteporfin (CL 318952) in vitro | Verteporfin (CL 318952) cell line | Verteporfin (CL 318952) concentration | Verteporfin (CL 318952) nmr